Antidepressant Withdrawal Syndrome: Recognition, Prevention and Management

CNS Drugs

Volumn 5, Issue 4, 1996, Pages 278-292

  Lejoyeux, Michel ^a   Adès, Jean ^b   Mourad, Isabelle ^b   Solomon, Jacquelyn ^a   Dilsaver, Steven ^c  

^a BICHAT HOSPITAL   (France)

^b HÔPITAL LOUIS MOURIER   (France)

^c University of Texas Harris County Psychiatric Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; FLUOXETINE; FLUVOXAMINE; MONOAMINE OXIDASE INHIBITOR; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT;

DRUG WITHDRAWAL; HEART ARRHYTHMIA; HUMAN; MANIA; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SLEEP DISORDER; WITHDRAWAL SYNDROME;

EID: 0029914920     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-199605040-00006     Document Type: Article

References (76)

1. Mann AM, MacPherson A. Clinical experience with imipramine (G22355) in the treatment of depression. Can Psychiatr Assoc J 1959; 4: 38-47
2. Andersen H, Kristiansen ES. Tofranil treatment of endogenous depressions. Acta Psychiatr Scand 1959; 34: 387-97
3. Kramer JC, Klein DF, Fink M. Withdrawal symptoms following discontinuation of imipramine therapy. Am J Psychiatry 1961; 118: 549-50
4. Law W, Petti TA, Kazdin A. Withdrawal symptoms after graduated cessation of imipramine in children. Am J Psychiatry 1981; 118: 647-50
5. Bialos D, Giller E, Jallow P, et al. Recurrence of depression after discontinuation of amitriptyline. Am J Psychiatry 1982; 139: 325-9
6. Tyrer P. Clinical effects of abrupt withdrawal from tricyclic antidepressants and monoamine oxidase inhibitors after long-term treatment. J Affect Disord 1984; 6: 1-7
7. Geller B, Cooper TB, Carr LG. Prospective study of scheduled withdrawal from nortriptyline in children and adolescents. J Clin Psychopharmacol 1987; 7: 252-4
8. Diamond BI, Borison RL, Katz R, et al. Rebound reactions due to clomipramine. Psychopharmacol Bull 1989; 25 (2): 209-12
9. Otani K, Sasa H, Kaneko S, et al. Lack of withdrawal symptoms after discontinuation of mianserin. Lancet 1991; 337: 673-4
10. Ceecherini-Nelli A, Bardellini L, Guazzalli M, et al. Antidepressant withdrawal phenomena: prospective findings [letter]. Am J Psychiatry 1993; 150 (1): 165
11. Mallya G, White K, Gunderson C. Is there a serotoninergic withdrawal syndrome? Biol Psychiatry 1993; 33: 851-2
12. Barr LC, Goodman WK, Price LH. Physical symptoms associated with paroxetine discontinuation [letter]. Am J Psychiatry 1994; 151 (2): 289
13. Keuthen NJ, Cyr P, Ricciardi JA, et al. Medication withdrawal symptoms in obsessive-compulsive disorder patients treated with paroxetine. J Clin Psychopharmacol 1994; 14 (3): 206-7
14. Einbinder E. Fluoxetine withdrawal [letter]? Am J Psychiatry 1995; 152 (8): 1235
15. Baer L, Ricciardi J, Keuthen N, et al. Discontinuing obsessive-compulsive disorder medication with behavior therapy [letter]. Am J Psychiatry 1995; 151 (12): 1842
16. Lejoyeux M, Rouillon F, Adès J, et al. A retrospective study of the effects of withdrawing antidepressants [abstract]. Neuropsychopharmacology 1994 May; 10 (35 Pt 2): 47S
17. MacMahon TC. A clinical overview of syndromes following withdrawal of antidepressants. Hosp Community Psychiatry 1986 Sept; 37 (9): 883-4
18. Dilsaver SC, Greden JF, Snider RM. Antidepressant withdrawal syndromes: phenomenology and physiopathology. Int Clin Psychopharmacol 1987; 2: 1-19
19. Dilsaver SC. Withdrawal phenomena associated with antidepressant and antipsychotic agents. Drug Saf 1994; 10 (2): 103-14
20. Boisvert D, Chouinard G. Rebound cardiac arrhythmia after withdrawal from imipramine: a case report. Am J Psychiatry 1981; 138: 985-6
21. Dilsaver SC, Feinberg M, Greden JF. Antidepressant withdrawal symptoms treated with anticholinergic agents. Am J Psychiatry 1983; 140 (2): 249-51
22. Gualtieri CT, Staye J. Withdrawal symptoms after abrupt cessation of amitriptyline in an eight-year-old boy. Am J Psychiatry 1979; 136: 457-8
23. Shatan C. Withdrawal after abrupt termination of imipramine. Can Psychiatr Assoc J 1966; Suppl.: 150-8
24. Webster PAC. Withdrawal symptoms in neonates associated with maternal antidepressant therapy. Lancet 1973; 2: 318-9
25. Gawin FH, Markoff RA. Panic anxiety after abrupt discontinuation of amitriptyline. Am J Psychiatry 1981; 138: 117-8
26. Davison P, Wardrope J. Acute amitriptyline withdrawal and hyponatraemia. Drug Saf 1993; 8 (1): 78-80
27. Brown GM, Stancer HC, Moldofsky H, et al. Withdrawal from long-term high-dose desipramine therapy; clinical and biological changes. Arch Gen Psychiatry 1978; 35: 1261-4
28. Dilsaver SC, Kronfol Z, Greden JF, et al. Antidepressant withdrawal syndromes: evidences supporting the cholinergic overdrive hypothesis. J Clin Psychopharmacol 1983; 3: 157-64
29. Sathananthan GL, Gershon S. Imipramine withdrawal: an akathisia-like syndrome. Am J Psychiatry 1973; 130: 1286-7
30. Weller RA, McKnelly Jr WV. Case report of withdrawal dyskinesia associated with amoxapine. Am J Psychiatry 1983; 140 (11): 1515-6
31. Lejoyeux M, Rodière-Rein C, Adès J. Syndrome de sevrage des antidépresseurs. Description de cinq cas. Encephale 1992; 18: 251-5
32. Dilsaver SC, Greden JF. Antidepressant withdrawal-induced activation (hypomania and mania): mechanism and theoretical significance. Brain Res Rev 1984; 7: 29-48
33. Ghadirian AM. Paradoxical mood response following antidepressant withdrawal. Biol Psychiatry 1986; 21: 1298-300
34. Hartman PM. Mania or hypomania after withdrawal from antidepressants. J Fam Pract 1990; 30: 471-2
35. Mirin SM, Schatzberg AF, Creasey DE. Hypomania and mania after withdrawal of tricyclic antidepressants. Am J Psychiatr 1981; 138: 87-9
36. Nelson JC, Schottenfield RS, Condrad ED. Hypomania after desipramine withdrawal. Am J Psychiatry 1983; 140: 624-5
37. Van Scheyen JD, van Kammen DP. Clomipramine-induced mania in unipolar depression. Arch Gen Psychiatry 1979; 36: 560-5
38. Halle MH, Del Medico VJ, Dilsaver SC. Symptoms of major depression: acute effect of withdrawing antidepressants. Acta Psychiatr Scand 1991; 83: 238-9
39. Van Sweden B. Rebound antidepressant cardiac arrhythmia. Biol Psychiatry 1988; 24: 363-4
40. Liskin B, Roose S, Walsh T. Acute psychosis following phenelzine discontinuation. J Clin Psychopharmacol 1984; 5: 46-7
41. Roth SD. More on psychosis following phenelzine discontinuation. J Clin Psychopharmacology 1985; 5: 360-1
42. Halle MT, Dilsaver SC. Tranylcypromine withdrawal phenomena. J Psychiatry Neurosci 1993; 18 (1): 49-50
43. Frankel DA, Raskin DE. Psychosis following phenelzine discontinuation [letter]. J Clin Psychopharmacol 1985; 5: 360
44. Le Gassicke J, Ashcroft GW, Eccleston D, et al. The clinical state, sleep and amine metabolism of a tranylcypromine (Parnate) addict. Br J Psychiatry 1965; 3: 357-64
45. Dilsaver SC, Greden JF: Antidepressant withdrawal phenomena. Biol Psychiatry 1984; 19: 237-56
46. Pagliaro LA, Pagliaro AM. Abuse potential of antidepressants: does it exist? CNS Drugs 1995; 4: 247-52
47. Lejoyeux M. Dépendance aux antidépresseurs: authentique addiction? L'Encéphale 1995; 21 (No. Special 1): 63-5
48. Vartzopulos D, Krull F. Dependence on monoamine oxidase inhibitors in high dose. Br J Psychiatry 1991; 158: 856-7
49. Debattista C, Schatzberg AF. Physical symptoms associated with paroxetine withdrawal. Am J Psychiatry 1995; 152 (8): 1235-6
50. Fava GA, Grandi S. Withdrawal syndromes after paroxetine and sertraline discontinuation. J Clin Psychopharmacol 1995; 15: 374-5
51. Pyke RE. Paroxetine withdrawal syndrome. Am J Psychiatry 1995; 152 (1): 149-50
52. D'Arcy PF. Dystonia and withdrawal symptoms with paroxetine [letter]. Int Pharm J 1993; 7: 140
53. Bioch M, Stager SV, Braun AR, et al. Severe psychiatric symptoms associated with paroxetine withdrawal [letter]. Lancet 1995 Jul; 346: 57
54. Frost L, Lal S. Shock-like sensations after discontinuation of selective reuptake inhibitors [letter]. Am J Psychiatry 1995; 152 (5): 810
55. Stoukides JA, Stoukides CA. Extrapyramidal symptoms upon discontinuation of fluoxetine [letter]. Am J Psychiatry 1991; 148 (9): 1263
56. Lipinski Jr JF, Mallya G, Zimmerman P, et al. Fluoxetine-induced akathisia: clinical and theoretical implications. J Clin Psychiatry 1989; 50: 339-42
57. Lejoyeux M, Adès J, Rouillon F. Serotonin syndrome: incidence, symptoms and outcome. CNS Drugs 1994; 2 (2): 132-43
58. Kasantikul D. Reversible delirium after discontinuation of fluoxetine. J Med Assoc Thailand 1995; 78: 53-4
59. Otani K, Tanaka O, Kaneko S, et al. Mechanisms of the development of trazodone withdrawal symptoms. Int Clin Psychopharmacol 1994; 9: 131-3
60. Petersen RC, Richelson E. Anticholinergic activity of imipramine and some analogues at muscarinic receptors of culture mouse neuroblastoma cells. Psychopharmacology 1982; 76: 26-8
61. Snyder SH, Yamamura HI. Antidepressants and muscarinic acetylcholine receptor. Arch Gen Psychiatry 1977; 34: 236-9
62. Tollefson GD, Senogles SE, Frey WH, et al. A comparison of peripheral and central human muscarinic cholinergic receptor affinities for psychotropic drugs. Biol Psychiatry 1982; 17: 555-67
63. Rouillon F, Lejoyeux M, Filteau MJ. Unwanted effects of long-term treatment. In: Montgomery S, Rouillon F, editors. Long-term treatment of depression. Vol. 3. Chichester: John Wiley and Sons, 1992: 81-111
64. Dilsaver SC. Antimuscarinic agents as substances of abuse: a review. J Clin Psychopharmacol 1988; 8: 14-22
65. Dilsaver SC. Cholinergic mechanisms in affective disorders. Further directions for investigation. Acta Psychiatr Scand 1986; 74: 312-34
66. Dilsaver SC. Cholinergic mechanisms in depression. Brain Res Rev 1986; 11: 285-316
67. Dilsaver SC. Pharmacologic induction of cholinergic system up-regulation and supersensitivity in affective disorders research. J Clin Psychopharmacol 1986; 7: 56-72
68. Charney DS, Heninger GR, Sternberg DE, et al. Abrupt discontinuation of tricyclic antidepressant drugs: evidence for noradrenergic hyperactivity. Br J Psychiatry 1982; 141: 377-86
69. Charney DS, Menkes DB, Heninger GR. Receptor sensitivity and the mechanism of action of antidepressant treatment: implications for the etiology and theory of depression. Arch Gen Psychiatry 1981; 38: 1160-80
70. Walsh BT, Stewart JW, Wright L, et al. Treatment of bulimia with monoamine oxidase inhibitors. Am J Psychiatry 1982; 139: 1629-30
71. Dilsaver SC. The pathophysiologies of substance abuse and affective disorders: an integrative model? J Clin Psychopharmacol 1987; 7: 1-10
72. Cohen RM, Campbell IC, Dauphin M, et al. Changes in alpha and beta receptor densities in rat brain as a result of treatment with monoamine oxidase inhibitor antidepressants. Neuropharmacology 1982; 21: 293-8
73. Chiodo LA, Antelman SM. Repeated tricyclics induce progressive dopamine autoreceptor subsensitivity independent of daily drug treatment. Nature 1980; 287: 451-4
74. Creese I, Sibley DR. Receptor adaptations to centrally acting drugs. Annu Rev Pharmacol Toxicol 1981; 21: 317-91
75. Kupfer DJ, Frank E. The minimum length of treatment for recovery. In: Montgomery S, Rouillon F, editors. Long-term treatment of depression. New York: John Wiley, 1992: 33-52
76. Dilsaver SC. Antidepressant withdrawal syndromes: phenomenology and pathophysiology. Acta Psychiatr Scand 1989; 79: 113-7.